{
    "title": "Novartis sets sights on return to growth in 2018",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-4442462/Novartis-Q1-profit-slips-spending-Alcon-Entresto-weighs.html",
    "date": "2017-04-25",
    "keywords": [
        "percent",
        "growth",
        "novartis",
        "firstquarter",
        "jimenez",
        "failure",
        "drug",
        "miller",
        "core",
        "income",
        "forecast",
        "cosentyx",
        "heart",
        "entresto",
        "cancer",
        "quarter",
        "line",
        "year",
        "analyst",
        "eye",
        "alcon",
        "track",
        "tuesday",
        "executive",
        "joe",
        "drugmaker",
        "spending",
        "poll",
        "drop",
        "boost",
        "roche",
        "venture",
        "psoriasis",
        "treatment",
        "kisqali",
        "blood",
        "call",
        "investment",
        "bit",
        "hit",
        "development",
        "blockbuster",
        "serelaxin",
        "trial",
        "revenue",
        "competition",
        "lillys",
        "taltz",
        "gleevecs",
        "start",
        "berenberg",
        "alistair",
        "campbell",
        "note",
        "performance",
        "average",
        "bolton",
        "agreement",
        "group",
        "recovery",
        "care",
        "business",
        "fruit",
        "equipment",
        "contact",
        "difference",
        "plan",
        "cheuvreux",
        "review",
        "january",
        "spinoff",
        "prospect",
        "update",
        "pipeline",
        "change",
        "date",
        "approval",
        "baf312",
        "medicine",
        "sclerosis",
        "reporting",
        "john",
        "editing",
        "greg",
        "mahlich",
        "thomas"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}